Outcomes data
Table of contents
Acute Myocardial Infarction
AMI 30-day all-cause risk adjusted readmissions (Medicare 65+)
Oct. 2023 YTD
AMI mortality performance at IFMC – observed vs. expected
Oct. 2023 YTD
Inova Fairfax, Inova Loudoun and Inova Alexandria hospitals have received this award every year since 2016. The Chest Pain – MI Registry™ is the most trusted source for outcomes-based, continuous quality improvement applying American College of Cardiology (ACC) and American Heart Association clinical guideline recommendations.
Expected values represent the Vizient Top Decile calculated benchmark. Vizient performance data are based on Vizient's Standard Practice Risk Methodology. It's database is one of the most comprehensive healthcare databases and is routinely utilized by the pharmaceutical and device industries, academia, healthcare insurers and policymakes for clinical, financial and outcomes analyses.
“We continue to outperform expected mortality, even while the complexity of our patient population has significantly increased as a result of serving as a regional hub for the most severe cases of cardiogenic shock.”
Patient transfers
One call 24/7 ▪ 703-776-8000
Direct admission ▪ Transfer ▪ Specialized transport
Our multidisciplinary team collaborates to develop optimal treatment strategies for patients with complex coronary artery disease.
2023 cardiac catheterization and percutaneous coronary intervention (PCI) volume
Full year data
Full year data
Rolling 4Q ending Q3 2023
Primary PCI door-to-balloon within 90 minutes
Rolling 4Q ending Q3 2023
Door-to-balloon time (in minutes) NCDR benchmark 62:00
Rolling 4Q ending Q3 2023
PCI success
Rolling 4Q ending Q3 2023
Utilization of radial artery access for catheterization
Rolling 4Q ending Q3 2023
Full year data
Complex coronary interventions
A full spectrum of services for patients with advanced coronary artery disease is available using advanced mechanical circulatory support devices including highly specialized services such as coronary chronic total occlusion and CHiP (complex high risk and indicated revascularization procedures).
Our high volume and excellent outcomes in a wide variety of interventional cardiology procedures have facilitated access to leading edge technologies such as atherectomy and intravascular lithotripsy. We also participate in clinical trials looking at novel therapies for the management of complex coronary artery disease.
The structure of our services is based around a multidisciplinary team of clinicians specializing in not only interventional cardiology but also cardiac surgery, advanced heart failure and cardiovascular critical care to provide a selective and tailored approach to revascularization and holistic management of these patients.
Learn more about Inova's interventional cardiology services.
From left: Amika McBurnie, PA-C, MPH, and Inova’s Complex Coronary Therapeutics Program Co-Directors Lindsey Cilia, MD, and Behnam Tehrani, MD
Adult and pediatric ablation volume
Full year data
Device implant volume
Full year data
Combined procedure volume 2020 - 2023
Full year data
Pacemaker device implant volume
Full year data
Full year data
Annualized based on Jan. - Nov. 2023
Intersocietal Accreditation Commission (IAC)
- Testing and ablation
- Device implantation
- Chronic lead extraction
Refer a patient
The Inova AFib Center helps patient return to triathlon training and racing
Dave Conover, seven months after his AFib ablation
Dave Conover awoke with a start on Sept. 23, 2022, around 2:15 a.m. and immediately knew something was wrong with his heart. “It felt like there was a trout flopping around in my chest,” said Dave. “Everything just felt off.”
He’d experienced very brief instances of irregular or skipped heartbeats over the years, but this time it wasn’t going away. After about 15 minutes, he went to the nearest emergency room (ER). After several tests, he was sent home with a diagnosis: atrial fibrillation (AFib).
TAVR and isolated AVR cases
TAVR full year data; 2023 AVR is annualized based on Jan. - Nov. data
WATCHMAN and MitraClip procedures
TAVR full year data
TAVR motality rate
Medtronic Harmony™ TPV and delivery system
Patients with heart failure and mitral regurgitation benefit from standardized team based approach
More than 29 patients who have MR and symptomatic HFrEF have completed Inova’s innovative heart failure treatment algorithm with improved symptoms and excellent outcomes following mitral valve repair.
“We aimed to determine the feasibility and subsequent outcomes of establishing a protocol that begins with referral of patients to a heart failure advanced practitioner provider for titration of guideline-directed medical therapy prior to a final assessment for treatment using transcatheter edge-to-edge repair (TEER),” said Matthew Sherwood, MD, MHS, Co-Director of the Inova Structural Heart Program.
Interventional cardiologist Matthew Sherwood, MD (left) and Abbas Emaminia, MD perform a MitraClip™ procedure for a patient with MR and symptomatic HFrEF
Total surgical valve volume - isolated and combined procedures
Full year data
Full year data
CABG combined volume
Full year data '19 - '22, '23 annualized based on Jan. - Sept. data
Isolated CABG mortality
'23 values reflect Q1 - Q3 for both Inova and STS benchmark
Since 2019, Inova has partnered with Urban Alliance, a national youth workforce development nonprofit, to introduce local teens to careers in healthcare. Cardiothoracic surgeon Ramesh Singh, MD provided an overview of cardiac surgery in “The Dome” viewing area.
Isolated CABG post-op blood products used
'23 values based on Q1 - Q3 data
Isolated CABG intra-op blood products used
'23 values based on Q1 - Q3 data
Society of Thoracic Surgery (STS) is a national leader in health care transparency and accountability that has developed a comprehensive rating system for the quality of cardiac surgery care based on the overall performance of hospitals across the country for survival, complications, and other measures. Approximately 12 – 15 percent of hospitals receive a “3-Star” rating, which denotes the highest category for quality care. The current rating is for the data period of January 2019 – December 2021. In June 2024, updated ratings will be released. Further details can be found at: publicreporting.sts.org
Sustained excellence in cardiac surgery services
Year after year, Inova Schar Heart and Vascular’s cardiac surgery team continues to lead the way in making state-of-the-art care available to our patients as part of its ongoing efforts of sustaining excellent outcomes and performance.
Top-rated for isolated coronary artery bypass graft (CABG) surgery
Consecutively since 2016, Inova has earned the highest three-star rating distinction from the Society of Thoracic Surgeons (STS) for patient care and outcomes in isolated CABG procedures.
Cardiothoracic surgeons Eric Sarin, MD; (left) and Alan Speir, MD; provide leadership to Inova’s cardiac surgery program
The multidisciplinary team responsible for training and launching Inova's robotic CABG service (from left): Dave Young, PA-C; Daniel Bjorkman, RNFA; Kaitlyn Kozlowski, RNFA; Ramesh Singh, MD; and June Hill, Clinical Director of Robotic Surgery
Minimally invasive robotic CABG is an evolution in standard bypass surgery
Inova Schar Heart and Vascular’s commitment to excellence, expert clinicians and steadfast dedication to providing world-class healthcare make it one of the leading heart surgery programs in the country. Inova’s heart bypass outcomes consistently place us among the top-performing cardiac surgery programs nationwide.1
Unique patients followed
Nov. '22 - Nov. '23
2023 Lung transplant volume and heart and lung transplant volume
Jan. '24 SRTR program specific report
Inova lung transplant patient origin
Distribution based on patients discharged in 2023.
Inova’s comprehensive pulmonary hypertension program offers all approved treatments for CTEPH
Inova elevated to a WASOG Center of Excellence for sarcoidosis care
In June 2023, Inova’s Sarcoidosis Center achieved a significant milestone by becoming a World Association of Sarcoidosis and other Granulomatous Disorders (WASOG) Center of Excellence. WASOG is an international organization dedicated to advancing the understanding, diagnosis and treatment of sarcoidosis and other granulomatous disorders. It unites healthcare professionals, researchers and experts from around the world to collaborate on research, share knowledge and develop best practices in managing these conditions.
Inova joins the ranks of only 22 other United States programs and 40 worldwide designated as WASOG Centers of Excellence. The program offers a multidisciplinary team of specialized medical professionals providing leadership, best practices, research, support and training for sarcoidosis patients and professionals.
“The WASOG Center of Excellence designation is the highest and most prestigious award a sarcoidosis center can receive,” said Shambhu Aryal, MD, FCCP, Medical Director of both the sarcoidosis and Shambhu Aryal, MD, FCCP, Medical Director of the Inova Lung Transplant Program and Inova’s Sarcoidosis Center. “This recognition is the culmination of our team's unwavering commitment to providing world-class, multidisciplinary care. There is no need for patients in our region to travel elsewhere for the specialized care for this condition. We look forward to continuing to serve patients from our region and beyond.”
Recognition of Inova’s sarcoidosis services highlights our commitment, expertise and patient-centered approach.
Inova’s Sarcoidosis Center Team
Impella implants and cardiogenic shock patient volume
Full year data
Cardiogenic shock patient survival rates
Full year data
ECMO days of support
Full year data
ECMO runs
Full year data
ECMO patient survival
Inova compared against other ELSO centers
Full year data. Survival to discharge or transfer benchmarked against other ELSO centers in North America.
Patient transfers
One call 24/7 ▪ 703-776-8000
Direct admission ▪ Transfer ▪ Specialized transport
An undiagnosed genetic disorder led to heart and lung failure and a second chance at life
Corey Saul started his 20s as a healthy young man. Unbeknownst to him, he was kicking off a tumultuous decade. By the time he turned 28, Corey had gotten a surprise genetic diagnosis, survived cardiogenic shock and received a combined heart-lung transplant.
Ventricular assist device (VAD) and heart transplant volume
Full year data
First-year adult graft and patient survival
January 2024 SRTR program specific report covering 7/1/2020 - 12/31/2022
Primary LVAD postimplant survival
Intermacs 2023 Q1 report for cumulative primary VAD survival, released June 2023
Heart transplant patient origin
Based on 2023 patient discharges
Inova Urgent Heart Failure Clinic statistics
Data do not include 19 patients who required immediate hospitalization
Urgent heart failure clinic patient volume
IFMC patients only
Integrated palliative care support throughout patient journey
When patients face the potential need for a left ventricular assist device or heart transplantation, Inova integrates palliative care as part of our collaborative, multidisciplinary team to ensure patients’ concerns around symptoms and goals for their care are understood by the care team.
At the onset of every patient’s journey with advanced heart failure, the patient undergoes a comprehensive, day-long evaluation to engage with specialists from cardiovascular surgery, nutrition, pharmacy, education, social work, finance and palliative care to learn about the upcoming potential course of treatment.
Justin Van Klein, MD, is a palliative care physician who works with patients with heart failure
Artificial intelligence prompts innovative care for patients with advanced heart failure
Innovative digital technologies are paramount to the future of cardiac care. Inova Schar Heart and Vascular actively seeks unique approaches to improve care for patients with heart failure using technology, including artificial intelligence (AI).
Neonatal procedures
Pediatric congenital heart surgery
Adult congenital heart surgery
Refer a patient
Pediatric congenital heart program
703-776-4428
Fetal congenital heart program
703-776-6371
Providing comprehensive care for patients with congenital heart disease throughout their lifetime
One out of every 100 children in this country is born with a congenital heart defect. Previously, a substantial number of these children died or were extremely ill in their pediatric years. Today, 95% of children with CHD live to adulthood because of better prenatal screenings, specialized surgeries and other medical advancements.
Seated (from left): Wayne Batchelor, MD; Anurag Sahu, MD ; Mark Tanenbaum, MD; Pradeep Nayak, MD; back row (from left): Catherine Tomasulo,MD; Sherif Tawfik, MD; Mitchell Cohen, MD; Lucas Collazo, MD; Qurratulaen Khawaja-Javid, PA
Emily Potter, a CHD patient, mother of three and Inova pediatric cardiac ICU nurse
A CHD patient, a mother of three and an Inova nurse, shares her story
How did you find out you had CHD?
I was only seven days old when my mom woke me up from a nap and noticed that my breathing was different and my legs were a very pale color. She took me directly to the pediatrician's office, where a student nurse first assessed me and immediately alerted the head nurse to come and examine me. Within minutes, the pediatrician was physically carrying me across the street to the emergency room (ER). That day my body was in shock and kidney failure, and I was stabilized in the ER and then transferred to a pediatric intensive care unit.
The Society for Vascular Surgery's Vascular Quality Initiative (VQI®) is a collaboration intended to improve the quality, safety and effectiveness of vascular care. Included cases are those derived from the adjudicated VQI database. Data presented include all Inova hospital locations, rolling four quarters (R4Q) ending Q3 2023.
Vascular procedure volume
Urgency of endovascular AAA repair
RQ4 ending Q3 2023
Vascular procedure outcomes
R4Q ending Q3 2023
Inova TEVAR distribution by pathology
R4Q ending Q3 2023
Peripheral vascular indication
R4Q ending Q3 2023
Infraingual bypass indication
R4Q ending Q3 2023
Vascular ultrasound studies
Full year data
Wound healing centers patient visits
Wound healing centers HBO treatment visits
Refer a patient
Recent clinical trials highlight importance of preintervention assessments for patients with critical limb ischemia
Early discussions between vascular surgeons and interventionalists are crucial
CLI requires prompt diagnosis and treatment to restore blood flow to the affected extremity and prevent complications that could lead to amputation. Inova’s vascular surgeons have played a pivotal role in the development of many CLI bypass techniques now being used worldwide.
However, despite these and numerous other medical advances, national rates of amputations are increasing. The statistics are sobering. The national rate of amputations is 75% higher than it was less than 10 years ago and shows disparities by race and ethnicity, with Black Americans at a much higher risk of amputation. Moreover, diabetes-related amputations are also on the rise. Every three minutes in this country, an amputation takes place due to diabetes, and 85% of these are preventable.
“As limb loss has profound implications for quality of life and long-term survival, the medical community needs more dialogue on prevention, screening, diagnostics and interventions.”
American Diabetes Association's Amputation Prevention Alliance seeks to increase awareness and reduce disparities in care
According to the ADA, more than 154,000 diabetes-related amputations occur annually in the U.S., and it is estimated that 85% of these procedures are preventable. Notably, amputation rates are significantly higher among minorities. Black Americans are four times more likely to have an amputation than non-Hispanic white Americans. Hispanic communities are 50% more likely to have an amputation, and Indigenous communities face amputation rates that are twice those of non-Hispanic white Americans.
The ADA Amputation Prevention Alliance is dedicated to raising awareness of the crisis around diabetes-related amputations and educating providers and communities about ways to work together to prevent unnecessary amputations. Members of a clinical advisory working group including Richard Neville, MD, Chair, Inova Department of Surgery; Director, Inova Vascular Surgery; and Associate Director of Inova Schar Heart and Vascular; and other leading medical experts and innovators enhance the ADA’s work by providing a valuable clinical perspective.